ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2026
Optimizing revascularization in the high-risk heart: Impella™-facilitated percutaneous coronary intervention in multivessel coronary artery disease with reduced left ventricular ejection fraction and mitral regurgitation.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous coronary intervention (PCI) is considered for patients at high risk for peri-operative mortality and complications during coronary artery bypass grafting, with further consideration of mechanical circulatory support (MCS) to prevent haemodynamic decompensation in patients with complex coronary artery disease and reduced ventricular function. However, current risk models do not account for crucial factors such as frailty or severity of valvular disease, potentially underestimating surgical risk. As such, the surgeon's clinical judgment may more accurately reflect a given patient's mortality risk. Here, we present a clinical scenario of a frail, inoperable 73-year-old male with mitral regurgitation and reduced left ventricular ejection fraction who underwent successful complex high-risk PCI supported by an Impella™ microaxial flow pump. A multidisciplinary approach was taken in determining the patient's anatomical and clinical risk profile, with consideration of both conventional risk scores as well as the patient's frailty. The multivessel procedure was carefully planned to minimize intra-procedural risk while achieving the most complete and durable revascularization possible. Planned early use of MCS played a central role in maintaining haemodynamic stability during the intervention. The patient recovered without vascular or device-related complications, and at 6 months, demonstrated improved left ventricular ejection fraction to 45%. This scenario highlights the feasibility and safety of this approach when performed in an experienced centre; however additional studies are needed to define optimal patient selection, procedural protocols, and follow-up pathways. Until then, meticulous multidisciplinary evaluation, tailored procedural planning, and rigorous post-procedural care remain the cornerstones of success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.